UBS Group
CLVS

UBS Group’s Clovis Oncology, Inc. CLVS Stock Holding History

UBS Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,239
Closed -$5K – 11649
2022
Q3 		$5K Sell
4,239
-57
-1% -$89 ﹤0.01% 9294
2022
Q2 		$8K Sell
4,296
-69
-2% -$102 ﹤0.01% 8415
2022
Q1 		$9K Sell
4,365
-1,092,099
-100% -$2.15M ﹤0.01% 8620
2021
Q4 		$2.97M Buy
1,096,464
+148,961
+16% +$551K ﹤0.01% 3364
2021
Q3 		$4.23M Buy
947,503
+648,662
+217% +$3.12M ﹤0.01% 2855
2021
Q2 		$1.73M Sell
298,841
-251,564
-46% -$1.47M ﹤0.01% 3713
2021
Q1 		$3.86M Buy
550,405
+286,372
+108% +$1.92M ﹤0.01% 2884
2020
Q4 		$1.27M Buy
264,033
+9,035
+4% +$45.7K ﹤0.01% 3825
2020
Q3 		$1.49M Buy
254,998
+43,898
+21% +$263K ﹤0.01% 3338
2020
Q2 		$1.43M Buy
211,100
+57,976
+38% +$439K ﹤0.01% 3194
2020
Q1 		$974K Buy
153,124
+115,363
+306% +$925K ﹤0.01% 3377
2019
Q4 		$394K Sell
37,761
-889,214
-96% -$6.47M ﹤0.01% 5052
2019
Q3 		$3.64M Buy
926,975
+211,197
+30% +$1.71M ﹤0.01% 2686
2019
Q2 		$10.6M Buy
715,778
+690,441
+2,725% +$12.5M ﹤0.01% 1696
2019
Q1 		$629K Sell
25,337
-319,704
-93% -$8.01M ﹤0.01% 3904
2018
Q4 		$6.2M Buy
345,041
+313,376
+990% +$6.4M ﹤0.01% 1974
2018
Q3 		$930K Sell
31,665
-18,184
-36% -$704K ﹤0.01% 3914
2018
Q2 		$2.27M Sell
49,849
-72,649
-59% -$3.53M ﹤0.01% 3056
2018
Q1 		$6.47M Buy
122,498
+52,206
+74% +$3.05M ﹤0.01% 2079
2017
Q4 		$4.78M Sell
70,292
-9,584
-12% -$670K ﹤0.01% 2391
2017
Q3 		$6.58M Buy
79,876
+42,987
+117% +$3.41M ﹤0.01% 1955
2017
Q2 		$3.45M Buy
36,889
+30,568
+484% +$1.87M ﹤0.01% 2486
2017
Q1 		$402K Sell
6,321
-66,604
-91% -$4.05M ﹤0.01% 4194
2016
Q4 		$3.24M Buy
72,925
+10,532
+17% +$371K ﹤0.01% 2467
2016
Q3 		$2.25M Sell
62,393
-50,118
-45% -$1.08M ﹤0.01% 2730
2016
Q2 		$1.54M Buy
112,511
+106,438
+1,753% +$1.56M ﹤0.01% 2994
2016
Q1 		$117K Sell
6,073
-63,666
-91% -$1.35M ﹤0.01% 4861
2015
Q4 		$2.44M Buy
69,739
+11,753
+20% +$758K ﹤0.01% 2615
2015
Q3 		$5.33M Buy
57,986
+12,214
+27% +$1.06M ﹤0.01% 1863
2015
Q2 		$4.02M Sell
45,772
-153,791
-77% -$13.2M ﹤0.01% 2304
2015
Q1 		$14.8M Sell
199,563
-48,176
-19% -$3.4M 0.01% 1160
2014
Q4 		$13.9M Buy
+247,739
New +$13M 0.01% 1246

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

UBS Group's CLVS Position: Q4 2022 in Review

UBS Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 4,239 shares — an estimated $5K sold.

UBS Group first reported a position in CLVS in Q4 2014 and held it in 32 quarters. The position peaked at $14.8M in Q1 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • UBS Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 4,239 Clovis Oncology, Inc. shares in Q4 2022, an estimated $5K.
  • UBS Group first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 32 quarters.
  • UBS Group's Clovis Oncology, Inc. position peaked at $14.8M in Q1 2015.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.